Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-2533Eco-Vector55210.25692/ACEN.2018.4.9ReviewsОбзорыUnknownProgressive multifocal leukoencephalopathy as a complication of disease-modifying treatment of multiple sclerosisПрогрессирующая мультифокальная лейкоэнцефалопатия как осложнение лечения препаратами, изменяющими течение рассеянного склерозаZakharovaMaria N.ЗахароваМария Николаевна
Russian Federation
Lysogorskaya@neurology.ruLysogorskaiaElena V.ЛысогорскаяЕлена Владимировна
Russian Federation
Lysogorskaya@neurology.ruIvanovaMaria V.ИвановаМария Васильевна
Russian Federation
Lysogorskaya@neurology.ruKocherginIvan А.КочергинИван Александрович
Russian Federation
Lysogorskaya@neurology.ruKorzhovaYulia E.КоржоваЮлия Евгеньевна
Russian Federation
Lysogorskaya@neurology.ruResearch Center of NeurologyФГБНУ «Научный центр неврологии»Research Сenter of NeurologyФГБНУ «Научный центр неврологии»07122018124626614122018Copyright ©; 2018, Zakharova M.N., Lysogorskaia E.V., Ivanova M.V., Kochergin I.А., Korzhova Y.E.Copyright ©; 2018, Zakharova M.N., Lysogorskaia E.V., Ivanova M.V., Kochergin I.А., Korzhova Y.E.2018Zakharova M.N., Lysogorskaia E.V., Ivanova M.V., Kochergin I.А., Korzhova Y.E.Zakharova M.N., Lysogorskaia E.V., Ivanova M.V., Kochergin I.А., Korzhova Y.E.https://creativecommons.org/licenses/by/4.0https://annaly-nevrologii.com/pathID/article/view/552

The review provides modern understanding of the pathogenesis of progressive multifocal leukoencephalopathy (PML), a severe and potentially fatal form of multiple-lesion disorder of the brain white matter. Information about the frequency of its development in patients with disease-modifying treatment of multiple sclerosis is analyzed. The algorithms of optimization of PML risks in this category of patients with multiple sclerosis are described in detail. Summarized are the data on most significant PML biomarkers, the search for which is currently under way in many centers across the world. The first case of PML in Russia is briefly described.

В обзоре дается современное представление о патогенезе прогрессирующей мультифокальной лейкоэнцефалопатии (ПМЛ) – тяжелой и потенциально фатальной формы многоочагового поражения белого вещества головного мозга. Анализируются сведения о частоте ее развития у пациентов с рассеянным склерозом, которые получают препараты, изменяющие течение заболевания. Подробно изложены алгоритмы оптимизации рисков развития ПМЛ у этой категории пациентов с рассеянным склерозом. Обобщены данные о наиболее значимых биомаркерах развития ПМЛ. Кратко описан первый зафиксированный случай развития ПМЛ в России.

multiple sclerosisprogressive multifocal leukoencephalopathyDMTnatalizumabrisk stratification.рассеянный склерозпрогрессирующая мультифокальная лейкоэнцефалопатияпрепараты, изменяющие течение рассеянного склерозанатализумабстратификация рискаZavalishin I.A., Zakharova M.N. [Multiple sclerosis: results and perspectives of the study]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 1982; 82(2): 161–167. (In Russ.)Завалишин И.А., Захарова М.Н. Рассеянный склероз: итоги и перспективы изучения. Журнал невропатологии и психиатрии им. С.С. Корсакова 1982; 82(2): 161–167.Zavalishin I.A., Zakharova M.N., Zhuchenko T.D., Peresedova A.V. [Etiology and pathogenesis of multiple sclerosis]. In: Zavalishin I.A., Golovkin V.I. (eds.) Rasseyannyi skleros. Izbrannye voprosy teorii i praktiki [Multiple Sclerosis. Selected issues of theory and practice]. Moscow: Ministry of Health of Russia, Research center of neurology, RAMS, 2000: 537–579. (In Russ.)Завалишин И.А., Захарова М.Н., Жученко Т.Д., Переседова А.В.Bisaga G.N., Kovalenko A.V., Isayeva G.E. et al. [The use of mesenchymal stem cells in optic atrophy in patients with multiple sclerosis: a pilot study]. Annals of clinical and experimental neurology 2017; 11(2): 26–31. (In Russ.)Этиология и патогенез рассеянного склероза. В кн: Завалишин И.А., Головкин В.И. (ред.) Рассеянный склероз. Избранные вопросы теории и практики. М.: Минздрав России, НИИ неврологии РАМН, 2000: 537–579.Ryabtseva M.S., Negudova N.P., Batuashvili T.A., Simutenko L.V. [Experimental evaluation of bioequivalence of original and reproduced peptide preparations in multiple sclerosis]. Annals of clinical and experimental neurology 2018; 12(2): 39–44. (In Russ.)Бисага Г.Н., Коваленко А.В., Исаева Г.Е. и др.Votintseva M.V., Petrov A.M., Stolyarov I.D. [Drugs based on monoclonal antibodies: the present and the future in the treatment of multiple sclerosis (based on the materials of the 32nd Congress of the European Committee for the Treatment and Research of Multiple Sclerosis – ECTRIMS)]. Annals of clinical and experimental neurology 2017; 11(2): 83–88. (In Russ.)Применение мезенхимальных стволовых клеток при атрофии зрительных нервов у больных рассеянным склерозом: пилотное исследование. Анналы клинической и экспериментальной неврологии 2017; 11(2): 26–31.Zakharova M.N., Logunov D.Yu., Kochergin I.A., Bakulin I.S. [Endogenous retroviruses: from basic research to etiotropic therapy for multiple sclerosis]. Annals of clinical and experimental neurology 2015; 9(4): 49–53. (In Russ.)Рябцева М.С., Неугодова Н.П., Батуашвили Т.А., Симутенко Л.В.Zakharova M.N. Lipid myelin. In: Multiple sclerosis. Selected questions of theory and practice. In: Zavalishin I.A., Golovkin V.I. (eds.) Rasseyannyi skleros. Izbrannye voprosy teorii i praktiki [Multiple Sclerosis. Selected issues of theory and practice]. Moscow: Ministry of Health of Russia, Research center of neurology, RAMS, 2000: 69–96. (In Russ.)Экспериментальная оценка биоэквивалентности оригинальных и воспроизведенных пептидных препаратов при рассеянном склерозе. Анналы клинической и экспериментальной неврологии 2018; 12(2): 39–44.Boyko A.N., Lash N.Yu., Sharanova S.N. et al. A comparative placebo-controlled clinical trial of the efficacy and safety of glatiramer acetate 20 mg in patients with relapsing multiple sclerosis: the results of the first year of follow-up. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2016. 10(2): 61–62. (In Russ.)Вотинцева М.В., Петров А.М., Столяров И.Д. Препараты на основе моноклональных антител: настоящее и будущее в лечении рассеянного склероза (по материалам 32-го Конгресса европейского комитета по лечению и исследованию рассеянного склероза – ECTRIMS). Анналы клинической и экспериментальной неврологии 2017; 11(2): 83–88.Korzhova Yu.E., Vorobyova A.A., Ivanova M.V. et al. A comparison of the efficacy of natalizumab or fingolimod as second-line drugs in patients with multiple sclerosis. Medica mente. Lechim s umom 2016; (1): 63–66. (In Russ.)Захарова М.Н., Логунов Д.Ю., Кочергин И.А., Бакулин И.С. Эндогенные ретровирусы: от фундаментальных исследований к этиотропной терапии рассеянного склероза. Анналы клинической и экспериментальной неврологии 2015; 9(4): 49–53.Hallervorden J. Eigennartige and nicht rubriziebare prozesse. In: Bumke O. (ed.) Handbuch der Geiteskranheiten, Die Anatomie der Phychosen. Berlin: Springer; 1930; 2: 1063–1107.Захарова М.Н. Липиды миелина. В кн: Завалишин И.А., Головкин В.И. (ред.) Рассеянный склероз. Избранные вопросы теории и практики. М.: Минздрав России, НИИ неврологии РАМН, 2000: 69–96.Astrom K.E., Mancell E.L., Richardson E.P.J. Progressive multifocal encephalopathy: A hitharto unrecognized complication of chronic lymphocytic leukemia and lymphoma. Brain 1958; 81: 99–111. PMID: 13523006.Бойко А.Н., Лащ Н.Ю., Шаранова С.Н. и др. Сравнительное плацебо-контролируемое клиническое исследование эффективности и безопасности препаратов глатирамер ацетата 20 мг у пациентов с ремиттирующим рассеянным склерозом: результаты первого года наблюдения. Журнал неврологии и психиатрии им. C.C. Корсакова 2016. 10(2): 61–62.ZuRhein G.M., Chou S.M. Particles resembling papova-virus in human cerebral demyelinating disease. Science 1965; 148: 1477–1479. PMID: 14301897.Коржова Ю.Е., Воробьева А.А., Иванова М.В., Лысогоркая Е.В. и др. Сравнение эффективности натализумаба или финголимода как препаратов второй линии у пациентов с рассеянным склерозом. Medica mente. Лечим с умом 2016; (1): 63–66.ZuRhein G.M. Association of papova-virions with a human demyelination disease (progressive multifocal leukoencephalopathy). Prog Med Virol 1969; 11: 185–248. PMID: 4906870.Hallervorden J. Eigennartige and nicht rubriziebare prozesse. In: Bumke O. (ed.) Handbuch der Geiteskranheiten, Die Anatomie der Phychosen. Berlin: Springer; 1930; 2: 1063–1107.Padgett B.L., Walker D.L., ZuRhein G.M. et al. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971; 1: 1257–1260. PMID: 4104715.Astrom K.E., Mancell E.L., Richardson E.P.J. Progressive multifocal encephalopathy: A hitharto unrecognized complication of chronic lymphocytic leukemia and lymphoma. Brain 1958; 81: 99–111. PMID: 13523006.Frisque R.J., Bream G.L., Cannella M.T. Human polyomavirus JC virus genome. J Virol 1984; 51: 458–469. PMID: 6086957.ZuRhein G.M., Chou S.M. Particles resembling papova-virus in human cerebral demyelinating disease. Science 1965; 148: 1477–1479. PMID: 14301897.Gardner S.D., Feild A.M., Colleman D.V., Hulme B. New human papovavirus (BK) isolated from urine after renal transplantation. Lancet 1971. 1: 1253–1257. PMID: 4104714.ZuRhein G.M. Association of papova-virions with a human demyelination disease (progressive multifocal leukoencephalopathy). Prog Med Virol 1969; 11: 185–248. PMID: 4906870.Knowles W.A. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 2006; 577: 19–45. DOI: 10.1007/0-387-32957-9_2. PMID: 16626025.Padgett B.L., Walker D.L., ZuRhein G.M. et al. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971; 1: 1257–1260. PMID: 4104715.Reid C.E., Li H., Sur G. et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis 2011; 204: 237–244. DOI: 10.1093/infdis/jir256. PMID: 21673034.Frisque R.J., Bream G.L., Cannella M.T. Human polyomavirus JC virus genome. J Virol 1984; 51: 458–469. PMID: 6086957.Warnke C., Adams O., Kieseier B. Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis. JAMA Neurol 2014; 71: 1192. DOI: 10.1001/jamaneurol.2014.1858. PMID: 25200546.Gardner S.D., Feild A.M., Colleman D.V., Hulme B. New human papovavirus (BK) isolated from urine after renal transplantation. Lancet 1971. 1: 1253–1257. PMID: 4104714.Zakharova M.N. [Progressive multifocal leukoencephalopathy (literature review)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2012; 112(9-2): 29–33. (In Russ.)Knowles W.A. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 2006; 577: 19–45. DOI: 10.1007/0-387-32957-9_2. PMID: 16626025.Physician Information and Management Guidelines for Multiple Sclerosis patients on TYSABRI Therapy. European Medicines Agency. 2016. https://www.medicines.org.uk/emc/rmm/1199/DocumentReid C.E., Li H., Sur G. et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis 2011; 204: 237–244. DOI: 10.1093/infdis/jir256. PMID: 21673034.Carrillo-Infante C., Richman S., Yu B. et al. Functional and survival outcomes of asymptomatic progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients: 2015 update. ECTRIMS Online Library 2016: EP1528.Warnke C., Adams O., Kieseier B. Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis. JAMA Neurol 2014; 71: 1192. DOI: 10.1001/jamaneurol.2014.1858. PMID: 25200546.Power C., Gladden J.G., Halliday W. et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 2000; 54: 743–746. PMID: 10680816.Захарова М.Н. Прогрессирующая мультифокальная лейкоэнцефалопатия (обзор литературы). Журнал неврологии и психиатрии им. C.C. Корсакова 2012; 112(9-2): 29–33.Antinori A., Ammassari A., Giancola M.L. et al. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol 2001; 7: 323–328. DOI: 10.1080/13550280152537184. PMID: 11517411.Physician Information and Management Guidelines for Multiple Sclerosis patients on TYSABRI Therapy. European Medicines Agency. 2016. https://www.medicines.org.uk/emc/rmm/1199/DocumentGarcia-Suarez J., de Miguel D., Krsnik I. et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80: 271–281. DOI: 10.1002/ajh.20492. PMID: 16315252.Carrillo-Infante C., Richman S., Yu B. et al. Functional and survival outcomes of asymptomatic progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients: 2015 update. ECTRIMS Online Library 2016: EP1528.Clavel G., Moulignier A., Semerano L. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments. Joint Bone Spine. 2017; 84: 671–675. DOI: 10.1016/j.jbspin.2017.03.002. PMID: 28323224.Power C., Gladden J.G., Halliday W. et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 2000; 54: 743–746. PMID: 10680816.Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009; 60: 3761–3765. DOI: 10.1002/art.24966. PMID: 19950261.Antinori A., Ammassari A., Giancola M.L. et al. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol 2001; 7: 323–328. DOI: 10.1080/13550280152537184. PMID: 11517411.Asztely F., Gilland E., Wattjes M.P., Lycke J. Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. J Neurol Sci 2015; 353: 155–157. DOI: 10.1016/j.jns.2015.04.010. PMID: 25908254.Garcia-Suarez J., de Miguel D., Krsnik I. et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80: 271–281. DOI: 10.1002/ajh.20492. PMID: 16315252.Carson K.R., Evens A.M., Richey E.A. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports Project. Blood 2009; 113: 4834–4840. DOI: 10.1182/blood-2008-10-186999. PMID: 19264918.Clavel G., Moulignier A., Semerano L. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments. Joint Bone Spine. 2017; 84: 671–675. DOI: 10.1016/j.jbspin.2017.03.002. PMID: 28323224.Ho P.R., Koendgen H., Campbell N. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 2017; 16: 925–933. DOI: 10.1016/S1474-4422(17)30282-X. PMID: 28969984.Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009; 60: 3761–3765. DOI: 10.1002/art.24966. PMID: 19950261.Mills E.A., Mao-Draayer Y. Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: a bird’s eye view. Front Immunol 2018; 9: 138. DOI: 10.3389/fimmu.2018.00138. PMID: 29456537.Asztely F., Gilland E., Wattjes M.P., Lycke J. Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. J Neurol Sci 2015; 353: 155–157. DOI: 10.1016/j.jns.2015.04.010. PMID: 25908254.Гусев Е.И., Гехт А.Б. (ред). Всероссийское общество неврологов. Клинические рекомендации. Рассеянный склероз. М.: Минздрав России, 2018. 129 c.Carson K.R., Evens A.M., Richey E.A. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports Project. Blood 2009; 113: 4834–4840. DOI: 10.1182/blood-2008-10-186999. PMID: 19264918.Gusev E.I., Gekht A.B. (eds.). Vserossiyskoye obshchestvo nevrologov. Klinicheskiye rekomendatsii. Rasseyannyy skleroz [Russian Society of Neurologists. Clinical recommendations. Multiple sclerosis]. Moscow: Ministry of Health of Russia, 2018. 129 p. (In Russ.)Ho P.R., Koendgen H., Campbell N. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 2017; 16: 925–933. DOI: 10.1016/S1474-4422(17)30282-X. PMID: 28969984.Motte J., Kneiphof J., Straßburger-Krogias K. et al. Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML. J Neurol 2018; 265: 1880–1882. DOI: 10.1007/s00415-018-8931-7. PMID: 29948248.Mills E.A., Mao-Draayer Y. Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: a bird’s eye view. Front Immunol 2018; 9: 138. DOI: 10.3389/fimmu.2018.00138. PMID: 29456537.Bloomgren G., Richman S., Hotermans C. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880. DOI: 10.1056/NEJMoa1107829. PMID: 22591293.Гусев Е.И., Гехт А.Б. (ред). Всероссийское общество неврологов. Клинические рекомендации. Рассеянный склероз. М.: Минздрав России, 2018. 129 c.Carotenuto A., Scalia G., Ausiello F. et al. CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients. J Neuroimmunol 2017; 309: 47–50. DOI: 10.1016/j.jneuroim.2017.05.006. PMID: 28601287.Motte J., Kneiphof J., Straßburger-Krogias K. et al. Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML. J Neurol 2018; 265: 1880–1882. DOI: 10.1007/s00415-018-8931-7. PMID: 29948248.Iannetta M., Zingaropoli M.A., Bellizzi A. et al. Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation. PLoS One 2016; 11: e0160277. DOI: 10.1371/journal.pone.0160277. PMID: 27486658.Bloomgren G., Richman S., Hotermans C. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880. DOI: 10.1056/NEJMoa1107829. PMID: 22591293.Jilek S., Mathias A., Canales M. et al. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients. Mult Scler 2014; 20: 837–842. DOI: 10.1177/1352458513513208. PMID: 24258149.Carotenuto A., Scalia G., Ausiello F. et al. CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients. J Neuroimmunol 2017; 309: 47–50. DOI: 10.1016/j.jneuroim.2017.05.006. PMID: 28601287.Savage N.D., Harris S.H., Rossi A.G. et al Inhibition of TCR-mediated shedding of L-selectin (CD62L) on human and mouse CD4+ T cells by metalloproteinase inhibition: analysis of the regulation of Th1/Th2 function. Eur J Immunol 2002; 32: 2905–2914. DOI: 10.1002/1521-4141(2002010)32:10<2905::AID-IMMU2905>3.0.CO;2-6. PMID: 12355444.Iannetta M., Zingaropoli M.A., Bellizzi A. et al. Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation. PLoS One 2016; 11: e0160277. DOI: 10.1371/journal.pone.0160277. PMID: 27486658.Basnyat P., Hagman S., Kolasa M. et al. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients. Mult Scler Relat Disord 2015; 4: 334–338. DOI: 10.1016/j.msard.2015.06.008. PMID: 26195052.Jilek S., Mathias A., Canales M. et al. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients. Mult Scler 2014; 20: 837–842. DOI: 10.1177/1352458513513208. PMID: 24258149.Schwab N., Schneider-Hohendorf T., Posevitz V. et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013; 81: 865–871. DOI: 10.1212/WNL.0b013e3182a351fb. PMID: 23925765.Savage N.D., Harris S.H., Rossi A.G. et al Inhibition of TCR-mediated shedding of L-selectin (CD62L) on human and mouse CD4+ T cells by metalloproteinase inhibition: analysis of the regulation of Th1/Th2 function. Eur J Immunol 2002; 32: 2905–2914. DOI: 10.1002/1521-4141(2002010)32:10<2905::AID-IMMU2905>3.0.CO;2-6. PMID: 12355444.Lieberman L.A., Zeng W., Singh C. et al. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology 2016; 86: 375–381. DOI: 10.1212/WNL.0000000000002314. PMID: 26718566.Basnyat P., Hagman S., Kolasa M. et al. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients. Mult Scler Relat Disord 2015; 4: 334–338. DOI: 10.1016/j.msard.2015.06.008. PMID: 26195052.Zakharova M.N., Lysogorskaia E.V., Trushnikova T.N., Zhelnin A.V. [The case of development of progressive multifocal leukoencephalopathy in a patient with multiple sclerosis on the background of taking natalizumab]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2018; 8(2): 106–108. (In Russ.)Schwab N., Schneider-Hohendorf T., Posevitz V. et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013; 81: 865–871. DOI: 10.1212/WNL.0b013e3182a351fb. PMID: 23925765.Lieberman L.A., Zeng W., Singh C. et al. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology 2016; 86: 375–381. DOI: 10.1212/WNL.0000000000002314. PMID: 26718566.Захарова М.Н., Лысогорская Е.В., Трушникова Т.Н., Желнин А.В. Случай развития прогрессирующей мультифокальной лейкоэнцефалопатии у пациента с рассеянным склерозом на фоне приема натализумаба. Журнал невропатологии и психиатрии им. С.С. Корсакова 2018; 8(2): 106–108.